OTTAWA, Ontario Nov. 16, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps(TM), unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).
Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now entering this lucrative market and plans on progressively grabbing a significant share of it over the next two years. Mr Fortier, CEO of Tetra, stated last week “We are expecting to generate around $1.5 million in sales, in fiscal 2018 in our initial launch. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps(TM) under prescription from their doctors over in the next twelve months.”
Rx Princeps(TM) is a new option for doctors who want to prescribe medical cannabis. Prescribing Rx Princeps(TM) with the Rx Princeps(TM) inhalation device enables their patients to optimize the benefits of medical cannabis through the intake of a fixed dose of product, thereby ensuring consistency of treatment with a standardized high-quality product.
Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada. As a result, Aphria’s products are in line with the strict quality standards Tetra is establishing for the medical community and its patients.
200,000 patients are already registered under the ACMPR program and around 1.5 million adults in Canada suffer from chronic pain and are considered non-responders to opioids; medical cannabis could be a new therapeutic choice for those patients but physicians need bioavailability and safety data to prescribe medical cannabis with confidence. According to Health Canada, less than 3,000 physicians actually prescribe cannabis to their patients. Tetra is committed to provide them rigorous safety and bioavailability data. Tetra has begun educating pain clinics and the medical profession across Canada on Rx Princeps(TM), including its advantages for patients.
In Quebec, Tetra is working closely with Sante Cannabis in order to educate patients and support them in their medical journey with cannabis. Sante Cannabis is the first cannabinoid clinic and medical marijuana resource centre in Quebec.
About Rx Princeps(TM):
Rx Princeps(TM) is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps(TM) is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001. Patients who want to purchase Rx Princeps(TM) in Canada need a prescription from their physicians and to register with Licensed Producer Aphria.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps(TM) product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps(TM) product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
FOR FURTHER INFORMATION PLEASE CONTACT:
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210